Philadelphia, 8 December, 2023 – Global law firm Hogan Lovells advised EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$230 million follow-on public offering of 13,529,411 shares of common stock at a public offering price of US$17.00 per share. J.P. Morgan, TD Cowen and Guggenheim Securities acted as joint book running managers for the offering. Cantor also acted as a book running manager for the offering. Mizuho and Laidlaw & Company (UK) Ltd. acted as co-managers for the offering.
EyePoint Pharmaceuticals is a clinical-stage company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The Hogan Lovells team was led by capital markets partners Steve Abrams and Stephen Nicolai (both based in Philadelphia) senior associate David Will (New York), and associate Kayvon Paul (Philadelphia).
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.